Arena Pharmaceuticals

Clinical-stage biotech focused on cardiovascular, central nervous system, inflammatory and metabolic diseases. Their leading drug candidate is lorcaserin hydrochloride, which recently received positive data from a clinical trial. They are headquartered in San Diego, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena Pharmaceuticals announces the appointment of Douglas J. Manion, M.D., F.R.C.P. (C), as EVP of Research & Development.

Arena Pharmaceuticals Appoints Doug Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & Development

AFC Gamma

Canopy Growth

Corbus Pharmaceuticals Holdings

Evogene

India Globalization Capital

OrganiGram Holdings Inc.

SNDL Inc.

Tilray Brands

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues to take shape in 2021.

Pot Stocks in Focus: Cannabis-Based Pharmaceutical Trials

Amyris

Cronos Group

HEXO Corp

Innovative Industrial Properties

Coffee Holding

Breaking Down a Wild Week in the World of Weed Stocks

PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Steven Schoch, CFO of 23andMe, appointed to Arena Pharmaceuticals' Board of Directors and as Chair of the Audit Committee.

Steven Schoch Elected to Arena Pharmaceuticals Board of Directors

Cardiff Oncology

GrowGeneration Corp

Hawaiian Electric Industries

Neptune Wellness Solutions Inc.

Village Farms International

22nd Century Group

Zynerba Pharmaceuticals

Smoked! How the Hottest Cannabis Stocks Fared This Week

The FDA bestows an Orphan Drug status to Arena's (ARNA) lead pipeline candidate, etrasimod, for the treatment of eosinophilic esophagitis.

Arena's (ARNA) Etrasimod Gets FDA's Orphan Drug Tag for EoE

Arena (ARNA) is developing temanogrel in a phase II study as potential treatment for coronary microvascular obstruction in patients undergoing percutaneous coronary intervention.

Arena (ARNA) Starts Phase II Study on Coronary Drug Temanogrel

PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation status to etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, for the treatment of eosinophilic esophagitis (EoE). Etrasimod is being investigated in the Phase 2b VOYAGE trial, a randomized, double-blind, placebo-controlled trial, with a primary efficacy measurement at week

Arena Pharmaceuticals Announces Orphan Drug Designation for Etrasimod for the Treatment of Eosinophilic Esophagitis (EoE)

PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena announces first participant randomized in Phase 2 trial evaluating IV temanogrel for the potential treatment of cMVO in patients undergoing PCI.

Arena Pharmaceuticals Announces First Participant Randomized in Phase 2 Trial Evaluating Temanogrel in Coronary Microvascular Obstruction (cMVO)

Arena Pharmaceuticals, Inc. (ARNA) reported earnings 30 days ago. What's next for the stock?

Why Is Arena Pharmaceuticals, Inc. (ARNA) Down 2.8% Since Last Earnings Report?

Aurora Cannabis

Applied DNA Sciences

FSD Pharma

cbdMD Inc

Breaking Down a Busy Week of Weed Stocks

PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena Pharmaceuticals today announced that as of 2021, Arena received an MSCI ESG Rating of "A."

Arena Pharmaceuticals Earns "A" Rating from MSCI ESG, a Leading Rating Agency for Sustainable Investments

American Woodmark

Atreca

Cannae Hlds

Dominion Energy

ESCO Technologies

FutureFuel

Heartland Express

Intelligent Systems

Kiniksa Pharmaceuticals Ltd

Kura Oncology

Madrigal Pharmaceuticals

NewMarket

PG&E

Premier

SelectQuote

Theravance Biopharma

Invesco DB US Dollar Index Bullish Fund

Often, weak stocks going into a market correction or bear move will decline faster than the main indexes. I have listed 20 stocks/ETFs out of a 4000+ sort universe experiencing a rush of selling since March.

20 Short Ideas With Super-Weak Momentum

Cara Therapeutics

Flora Growth Corp

Akerna Corp

Here Are the Cannabis Stocks That Caught Fire This Week

PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena Pharmaceuticals announced the Company earned Prime status from the ISS ESG Corporate Rating, the industry standard for sustainable investing.

Arena Pharmaceuticals Earns Prime Status from ISS ESG, a Leading Rating Agency for Sustainable Investments

GW Pharmaceuticals

Jazz Pharmaceuticals

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will continue to develop in 2021.

What Happened with Marijuana Stocks This Week?

Arena Pharmaceuticals (ARNA) beats Q1 bottom-line estimates. The company progresses with the development of its key pipeline candidate, etrasimod.

Arena (ARNA) Q1 Earnings Beat Estimates, Etrasimod Progresses

Arena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi on Q1 2021 Results - Earnings Call Transcript

Arena Pharmaceuticals, Inc. (ARNA) delivered earnings and revenue surprises of 9.59% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Arena Pharmaceuticals, Inc. (ARNA) Reports Q1 Loss, Misses Revenue Estimates

SAN DIEGO--(BUSINESS WIRE)---- $ARNA #ARNA--Arena Pharmaceuticals today provided a corporate update and reported financial results for the first quarter ended March 31, 2021.

Arena Reports First Quarter Financial Results with Strong Cash Position and Continued Progress on Pipeline Over the Quarter

PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ArenaPharm--Arena Pharmaceuticals will report first quarter 2021 financial results on May 5, and will host a live Q&A with the investment community at 4:30 pm ET.

Arena Pharmaceuticals to Release First Quarter 2021 Financial Results and Provide Corporate Update on May 5

Aphria

Turning Point Brands

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will continue to develop in the 2021.

4/20 Holiday Week Had These Cannabis Stocks Fired Up

PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #AADVMX2021--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced additional data at a late-breaking session at the American Academy of Dermatology VMX Experience. Etrasimod, a novel investigational drug candidate to treat moderate-to-severe atopic dermatitis (AD), demonstrated statistical significance in both clinician and patient reported outcomes in the etrasimod 2 mg treatment group of Arena's ADVISE Phase 2b clinical trial. Etrasimod is a highly selective, once-d

Arena Pharmaceuticals Presents Clinician and Patient Reported Outcomes Data from Phase 2b ADVISE Trial Evaluating Etrasimod in Adult Atopic Dermatitis During a Late-Breaking Session at American Academy of Dermatology VMX

PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena Pharmaceuticals today announced its second annual ESG report, outlining the Company's long-term commitment to the betterment of society.

Arena Pharmaceuticals Releases Second Annual Environmental, Social and Governance (ESG) Report

PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena Pharmaceuticals to present data from the Phase 2b ADVISE trial at the American Academy of Dermatology VMX on Friday, April 23.

Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial During Late-Breaking Research Session at American Academy of Dermatology Virtual Meeting Experience

News for Arena Pharmaceuticals Stock (ARNA)